D-Attachment 2_Purchase Description.pdf

Purchase Description

Statement of Need and Purpose:

Purchase compounds for COVID19 3CL enzymatic inhibitor screen

Background Information and Objective:

The ongoing pandemic of the coronavirus disease 2019 (COVID-19) has claimed many lives and severely damaged the global economy. This severe acute respiratory syndrome (SARS) is caused by a novel coronavirus SARS-CoV-19, which is closely related to SARS-Cov. The 3CL is the central component of coronaviral replication and transcription machinery, of the SARS-CoV-2, which is responsible for the viral replication and therefore considered as an attractive drug target since to date there is drug highly specific to inhibit this enzyme. The objective is to purchase selected compounds from virtual screen to verify their inhibitor activity on 3CL.

Generic Name of Product:

Selected chemical compounds from virtual screen

Purchase Description:

Compound library that contains 167 compounds from virtual screen.

Salient Characteristics:

1. The compounds must be suitable for biological screening and can be delivered in within 7 weeks.

2. The small molecules must have a purity of >90% (accuracy +/-5%) that is to be confirmed by Nuclear Magnetic Resonance (NMR) and mass spectrometry (LCMS) spectra.

Quantity:

one compound library that contains selected 167 compounds.

Delivery Date:

7 weeks ARO

Period of Performance:

none

Option(s):

none